A study investigating what potential benefits adding AZD2811 might have to the current standard of care maintenance therapy of durvalumab in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) who have not had any treatment yet for their cancer

Phase 1

• Conditions: First-line patients with extensive disease small-cell lung cancer (SCLC); MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2024-511887-10-00
• Lead Sponsor: AstraZeneca AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-12
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Documented evidence of extensive stage SCLC (ES-SCLC), Participants must be considered suitable to receive a platinum-based chemotherapy regimen, combined with durvalumab, as first-line treatment for ES-SCLC, No prior exposure to immune-mediated therapy, Life expectancy =12 weeks, ECOG 0 or 1 at enrolment

Exclusion Criteria

Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy, Has a paraneoplastic syndrome (PNS) of autoimmune systemic steroids or immunosuppressive agents) or has a clinical symptomatology suggesting worsening of PNS, Active infection including tuberculosis, HIV, hepatitis B and C, Active or prior documented autoimmune or inflammatory disorders, Uncontrolled intercurrent illness, including but not limited to interstitial lung disease

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified